IndustryApril 2026
Novo Nordisk Partners with OpenAI for AI Drug Discovery — JFInnova Was Built This Way From Day One
Novo Nordisk announces an enterprise-wide partnership with OpenAI to accelerate drug discovery, manufacturing, and delivery using AI. The collaboration is molecule-agnostic and aims to compress timelines from research to patient. Separately, Novo also partnered with NVIDIA for generative AI drug discovery using BioNeMo and digital twin simulations via Omniverse.
JFInnova Perspective
Big pharma is investing billions to bolt AI onto legacy pipelines. JFInnova was built natively with AI from day one: ESM-2 for nanobody design, ESMFold for structural prediction, digital twins for in silico trials. What they are building, we already use.
References
Novo Nordisk OpenAI AI drug discovery partnership